Table I.
Baseline characteristics of patients receiving panitumumab
| Characteristic | Value |
|---|---|
| Patients (n) | 37 |
| Age (years)a | |
| Mean | 60±10.6 |
| Range | 42–81 |
| Age ≥65 years (n) | 12 |
| ecog performance status [n (%)] | |
| 0 | 9 (24.3) |
| 1 | 20 (54) |
| 2 | 6 (16.2) |
| 3 | 1 (2.7) |
| Prior lines of chemotherapy [n (%)] | |
| 1b | 37 (100) |
| 2c | 37 (100) |
| 3d | 19 (51.4) |
| 4e | 3 (8.1) |
a
At treatment start.
b
folfox or folfiri ± bevacizumab; capecitabine ± oxaliplatin; 5-fluorouracil–leucovorin.
c
folfox or folfiri ± bevacizumab; irinotecan; capecitabine.
d
Oxaliplatin; irox (irinotecan–oxaliplatin); folfiri; irinotecan.
e
folfox.
ecog = Eastern Cooperative Oncology Group.